Frontlight ResearchEarly access
Taking peoplePhase 4
Toric Performance And Constant Evaluation
Key facts
- Who runs it
- Carl Zeiss Meditec AG
- Where
- Czechia, Germany, Spain, and United Kingdom6 sites in 4 countriesChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 130 people, planned
- Started
- 13 Jul 2026
- Expected to end
- 28 Feb 2028
- Type of study
- Interventional
- Treatments tested
- Monofocal toric IOL
- Record updated
- 22 July 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 31 criteriaShow less
Who can take part
- Aged 18 years or older
- Patients willing, able, and with sufficient cognitive awareness to comply with examination procedures and schedule for follow-up visits
- Patients with clinically significant age-related cataract (cataract grades of 1, 2, 3 on the LOCSIII scale, but otherwise healthy, requiring surgical treatment, and scheduled for unilateral or bilateral phacoemulsification or Femtosecond-Laser-Assisted cataract surgery
- Patients with existing regular corneal astigmatism of minimum 0.75 D in at least the first eye to be operated
- Signed informed consent form
- Corrected distance visual acuity projected to be better than 0.2 logMAR after the cataract surgery, as determined by Investigator's medical judgment
- Calculated IOL power within the range of the investigational IOL; SE +18.0 D to +28.0 D (0.5 D Steps), and between a Cylinder range of +1.0 D to +2.5 D (0.5 D Steps)
- Dilated pupil size large enough to visualize TIOL axis markings postoperatively; at least 5.5mm
- Clear intraocular media other than cataract
Who cannot take part
- Previous intraocular or corneal surgery in either eye that might confound the outcome of the study or increase the risk to the subject
- Concurrent participation in another drug or device investigation within the last 30 days
- History of concurrent intraocular inflammation
- Patients who may be reasonably expected to require a secondary surgical intervention at any time during the investigation (other than Nd:YAG capsulotomy)
- In case of both eyes included in this trial: Patients who need to undergo surgery on both eyes on the same day
- History of any clinically significant retinal or ocular pathology or ocular diagnosis (e.g. diabetic retinopathy, ischemic diseases, macular degeneration, retinal detachment, optic neuropathy optic nerve atrophy, amblyopia, strabismus, microphthalmus, epiretinal membrane, Choroidal hemorrhage etc.) in the study eyes that could alter or limit final postoperative visual prognosis
- Pseudoexfoliation syndrome (according to investigator judgement)
- Uncontrolled glaucoma or IOP higher than 24mmHg under ocular hypertension treatment
- All kind of infections (acute ocular disease, external / internal infection, systemic infection)
- Patients, who are unable to fixate for a longer time, e.g. strabismus, nystagmus, Parkinson disease
- Keratometric astigmatism (assessed by IOL Master) of minimum 0.75 D in the first eye
- Traumatic cataract
- Pregnancy or lactation
- Irregular astigmatism
- Instability of keratometry or biometry measurements
- Subjects wearing contact lenses as standard vision aid
- Abnormal pupil
- Any anterior segment pathology that could significantly affect outcomes (e.g. chronic or recurrent uveitis, iritis, aniridia, rubeosis iridis, etc.)
- Abnormal corneal findings in either eye (e.g. keratoconus, pellucid marginal degeneration, or clinically significant corneal membrane dystrophies)
- Monophthalmic patient
- Patient expected to require retinal laser treatment before the end of the last follow-up examination
- Patient expected to require refractive laser treatment / refractive laser touch-up before the end of the last follow-up examination
This trial has no sites in United States.
It has sites in 4 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The main purpose of this investigation is to support safety and performance assessment of the investigational device with a focus on optimizing the IOL constants based on refractive outcomes.
The group in the trial
- Unilateral or bilateral implantation of investigational deviceTreatment being tested
Treatment: Monofocal toric IOL
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Prospective Assessment of Constant Optimization and Visual Outcomes Following Monofocal Toric IOL Implantation
- Record updated
- 22 July 2026